Briefings & News
The signal, as it happens.
What we have filed, what the FDA has said, and what we have published. Scientific Briefings for researchers and institutions; press releases for everyone, newest first.
01 · For research & institutional audiences
Scientific Briefings
Each brief sets out the proposed mechanism, the evidence it rests on and the study design, with full references.
Alzheimer’s
TCX-SB-AD-01
October 22, 2026 · Latest
TriCelX Files an Investigational New Drug Application for XytriX™ in Mild Alzheimer’s Disease
Proposed paracrine signaling to the neuroinflammatory and neurovascular network by intravenous and intranasal administration.
Read the brief (PDF) →
CTE
ALS
Alzheimer’s
TCX-SB-NP-01
October 22, 2026
The Keyhole and the Sky: XytriX™ as an Integrated Neurological Platform
One investigational biotherapeutic studied across three diseases that share a common driver: chronic neuroinflammation.
Read the brief (PDF) →
ALS
TCX-SB-ALS-02
October 2026 · Updated
XytriX™ in Amyotrophic Lateral Sclerosis
Proposed paracrine signaling to the neuroinflammatory network by intravenous and intranasal administration, following the protocol update under IND 33245.
Read the brief (PDF) →
ALS
TCX-SA-ALS-01
September 24, 2026
FDA Authorizes TriCelX’s Phase 1/2 Study of Intravenous and Intranasal XytriX™ in ALS Under IND 33245
Scientific announcement: two routes, chosen for the anatomy of a disease spread across motor cortex, brainstem and spinal cord.
Read the brief (PDF) →
02 · Announcements
Press Releases
Nine announcements, newest first. Filled nodes mark FDA decisions.
Agency decisions
Submissions
Accreditation
Partnerships and sites
2026
Oct 21
TriCelX Takes On Alzheimer’s — Its Third Brain Disease, and the Largest
Read release ↗
Oct 5
TriCelX Earns AABB Accreditation — Three FDA-Cleared Trials, One Biotherapeutic, One Standard
Read release ↗
Sep 28
FDA Clears TriCelX’s Third IND: XytriX™ ALS Study May Proceed — Extending the Company’s CTE Program into ALS
Read release ↗
Jun 15
FDA Clears First-in-Indication Cell Therapy Trial for Chronic Traumatic Encephalopathy — for the Warriors Who Carry CTE
Read release ↗
May 26
TriCelX Launches XytriX™ as Department of Defense Collaboration Under the Blast Overpressure Safety Act
Read release ↗
May 18
TriCelX Files FDA IND for XytriX™ in Chronic Traumatic Encephalopathy (CTE)
Read release ↗
Apr 23
TriCelX Receives FDA Study May Proceed Letter for XytriX™
Read release ↗
Mar 30
TriCelX Files IND with FDA and Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis
Read release ↗
2025
Oct 22
TriCelX, Inc. Announces Opening of TriCelX Utah at the University of Utah Research Park
Read release ↗
Media & investors